Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb Clinical Trial Assessing EXN407 New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema

Next Previous
Trial Profile

A phase IIb Clinical Trial Assessing EXN407 New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EXN 407 (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms CLEAR-DM

Most Recent Events

  • 01 Sep 2026 According to Foventa Therapeutics media release, Exonate is now called Foventa Therapeutics.
  • 07 Mar 2024 New trial record
  • 05 Mar 2024 According to Exonate media release, Exonate is now planning to progress EXN407 to the CLEAR-DM (Clinical Evaluation of a New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema) Phase IIb clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top